100 Days and Counting: ADR Final Rule Still Under White House Review

Stephen Kuperberg, principal at the Law Offices of Stephen Kuperberg, said the Supreme Court underscored the importance of having a well-functioning ADR process.
After missing its self-imposed deadline of publishing the 340B administrative dispute resolution final rule by the end of 2023, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Takeda Adds Drug to 340B Contract Pharmacy Restrictions

Takeda 340B
Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
After implementing its first contract pharmacy restrictions in January, Japanese pharmaceutical giant Takeda recently subjected another drug to conditions on [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Amgen Extends Contract Pharmacy Restrictions to Grantees, Receives Early Pushback

Amgen wordmark on building facade
Drugmaker Amgen last week extended its existing 340B contract pharmacy restrictions to federal grantees.
Biopharmaceutical manufacturer Amgen recently expanded its conditions on 340B pricing at contract pharmacies to include grantees. The Thousand Oaks, California-based [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Cybersecurity Disruption of Major Claims Processor Continues to Affect 340B Providers

Change Healthcare, a major pharmacy claims processor, disconnected pharmacy services following a recent cyberattack.
Change Healthcare’s systems are down for a seventh straight day after it disconnected pharmacy services following a Feb. 21 cyberattack. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Oregon House to Vote Today on 340B Contract Pharmacy Bill

Oregon state lawmakers pulled a bill to bar drugmaker 340B contract pharmacy restrictions shortly after a similar Utah bill died in committee.
The Oregon state house is scheduled to vote today on a bill that would prohibit drugmaker 340B contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B ESP New Data Request Raises Concerns About Overreach

Courtney McFarland, partner at AAFCPAs, said 340B ESP was asking for types of data that she had not seen the vendor previously request.
The drugmaker vendor 340B ESP’s recent requests for additional claims data from some 340B hospitals has raised concerns from 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Contract Pharmacy Bills Introduced in Utah, Kansas, New York; Committees Approve Bills in Oregon, Oklahoma

Utah state Sen. Evan Vickers (R), senate majority leader, this week introduced one of multiple new state 340B contract pharmacy bills.
The majority leader of the Utah state senate and a key committee in the Kansas state senate each introduced bills [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AIDS Group Protests Health Center-Drug Industry Alliance Outside NACHC Policy Forum

AHF protested NACHC's partnership with drug industry advocates outside of a health center policy forum in Washington, D.C.
The AIDS Healthcare Foundation (AHF) staged a protest over the partnership between health centers and drug industry advocates outside a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health System, Drugmakers Battle Over Dismissal Request in 340B Penny Pricing Fraud Suit

Calif-based Adventist Health System/West and four drugmakers are clashing in federal district court over allegations of 340B overcharges.
A California health system and four drugmakers have filed dueling arguments over the pharmaceutical companies’ effort to dismiss a fraud [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

FTC, HHS Seek Comments on Role of GPOs, Wholesalers on Generic Drug Shortages

Federal Trade Commission sign over entrance.
The FTC and HHS asked for stakeholder feedback on generic drug shortages, which could have implications for the 340B program.
The Federal Trade Commission (FTC) and the Department of Health and Human Services (HHS) are requesting comments on how group [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live